- CA$193.87m
- CA$188.07m
- CA$43.05m
Canada's BioSyent Q1 revenue rises helped by Oral Science acquisition
Brief: Biosyent Announces Closing Of The Acquisition Of Oral Science Inc.
Brief: Biosyent To Acquire Oral Science Inc.
Brief: Biosyent Announces Renewal Of Normal Course Issuer Bid
Brief: BioSyent Inc QTRLY EPS C$0.14
Brief: BioSyent Inc Unit Has Commenced First Shipments Of Inofolic To Canadian Marketplace
Brief: BioSyent Releases Financial Results For Q1 2023
Brief: Biosyent Reports Fourth Quarter Results
Brief: BioSyent Signs Exclusive Agreement For Oncology Supportive Care Product
Brief: Biosyent Initiates First Dividend
Brief: Biosyent Releases Q2 And H1 2022 Financial Results
Brief: BioSyent Releases Financial Results for Q1 2022
Brief: BioSyent Reports Q4 EPS Of C$0.15
Brief: Biosyent Announces Renewal Of Normal Course Issuer Bid
Brief: Biosyent Q2 Earnings Per Share C$0.08
Brief: BioSyent Signs Exclusive Technology Agreement
Brief: BioSyent Q1 Earnings Per Share C$0.13
Brief: Biosyent Releases Financial Results For Q4 And FY2020
Brief: Biosyent Q3 Earnings Per Share C$0.07